Novogene Co. Ltd.

Company Overview

Novogene Co. Ltd. provides genomics services, including NGS and bioinformatics. The company operates a large sequencing facility in China. It offers high-throughput sequencing platforms; automated intelligent products (e.g., FALCON platform) and proprietary NGS-based diagnostic kits. Additionally, the Class III medical device offered by the company is a gene mutation detection kit approved by China’s National Medical Products Administration (NMPA), used for detecting significant mutations in tumors for specific cancers often seen in China. The company focuses on precision oncology, including assays for gene mutations related to therapies for non-small cell lung cancer. It has laboratories, subsidiaries, or joint ventures in Hong Kong, San Diego, Singapore, the University of California, Davis, and the U.K. Novogene has a CAP-accredited medical laboratory in Tianjin, China. The company tests liquid biopsy samples in this laboratory on its digital PCR platform.

Financial Highlights (FY 2025)

Company's Business Segments

• Genomics : Whole genome sequencing, Target capture sequencing, De novo sequencing, Metagenome sequencing
• Transcriptomics : Eukaryote, Prokaryote
• Single Cell Omics : Singel cell gene expression, Single cell long read transcriptome
• Epigenomics : Whole genome bisulfite sequencing, Reduced representation bisulfite sequencing, RIP-seq